AN2 Therapeutics (ANTX) Change in Accured Expenses (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Change in Accured Expenses data on file, last reported at -$662000.0 in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 61.07% year-over-year to -$662000.0 in Q1 2026; TTM through Mar 2026 was -$2.7 million, a 4449.18% decrease from a year earlier, with the FY2025 full-year figure at -$2.4 million, down 2006.35% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$662000.0, down from -$653000.0 in the prior quarter.
• Over the last five years, Change in Accured Expenses for ANTX reached as high as $2.2 million in Q2 2023 and fell as low as -$3.6 million in Q3 2023.
• Historically, Change in Accured Expenses has averaged $9647.1 across 5 years, with a median of -$249000.0 in 2025.
• Across the five-year window, Change in Accured Expenses soared 495.24% in 2023 and plunged 555.65% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $560000.0 in 2022, then surged by 225.36% to $1.8 million in 2023, then plunged by 126.56% to -$484000.0 in 2024, then sank by 34.92% to -$653000.0 in 2025, then declined by 1.38% to -$662000.0 in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$662000.0 in Q1 2026, -$653000.0 in Q4 2025, and -$249000.0 in Q3 2025.